arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

FILANA THERAPEUTICS, INC.

FLNA
$0.98 ▲ +0.03 (+2.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
67 Visible periods
25 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

FILANA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -12.9%
FCF / Share None
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.96M
↓ -28.1%
Net Income Profit after all expenses
$-10.33M
↑ +55.9%
Operating Margin Operating profit as % of sales
-39.6%
↓ -143.4%
FCF / Share Free cash flow per share
$-0.13
↓ -27.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters